TY - JOUR
T1 - Severe oral erosive lichenoid reaction to pembrolizumab therapy
AU - Bhattacharyya, Indraneel
AU - Chehal, Hardeep
AU - Migliorati, Cesar
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.
AB - New advances in cancer immunotherapy have been flooding the market at a rapid rate. Pembrolizumab (Keytruda), a programmed cell death protein 1 inhibitor, introduced in 2014, has been used to treat several cancers. Immune-related adverse events associated with pembrolizumab and other immune checkpoint inhibitors are now well-described complications. We describe the case of a 65-year old female with severe oral lichenoid lesions occurring after treatment with pembrolizumab for bladder cancer. To the best of our knowledge, this is the first report of a biopsy-proven oral erosive lichenoid reaction confirmed through direct immunofluorescence.
UR - http://www.scopus.com/inward/record.url?scp=85087710569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087710569&partnerID=8YFLogxK
U2 - 10.1016/j.oooo.2020.06.014
DO - 10.1016/j.oooo.2020.06.014
M3 - Article
C2 - 32654932
AN - SCOPUS:85087710569
VL - 130
SP - e301-e307
JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
SN - 2212-4403
IS - 5
ER -